lamotrigine has been researched along with Huntington Disease in 6 studies
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
Excerpt | Relevance | Reference |
---|---|---|
"To assess the efficacy of lamotrigine, a novel antiepileptic drug that inhibits glutamate release, to retard disease progression in Huntington disease (HD)." | 9.09 | Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. ( Almqvist, EW; Clark, CM; Graf, P; Hardy, MA; Hayden, MR; Jacova, C; Kremer, B; Martin, W; Mezei, M; Raymond, LA; Snow, B, 1999) |
"To assess the efficacy of lamotrigine, a novel antiepileptic drug that inhibits glutamate release, to retard disease progression in Huntington disease (HD)." | 5.09 | Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. ( Almqvist, EW; Clark, CM; Graf, P; Hardy, MA; Hayden, MR; Jacova, C; Kremer, B; Martin, W; Mezei, M; Raymond, LA; Snow, B, 1999) |
"The neurodegenerative disorders (Parkinson's disease, Alzheimer's dementia, Huntington's disease, cerebellar degeneration) are common medical and social problems." | 2.40 | [Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities]. ( Klivényi, P; Vécsei, L, 1997) |
"Huntington's disease is a progressive neurodegenerative disorder that gradually reduces memory, cognitive skills and normal movements of affected individuals." | 1.38 | Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. ( Kalonia, H; Kumar, A; Kumar, P, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kumar, P | 1 |
Kalonia, H | 1 |
Kumar, A | 1 |
Wu, J | 1 |
Tang, T | 1 |
Bezprozvanny, I | 1 |
Shen, YC | 1 |
Martin, WR | 1 |
Hoskinson, M | 1 |
Kremer, B | 2 |
Maguire, C | 1 |
McEwan, A | 1 |
Klivényi, P | 1 |
Vécsei, L | 1 |
Clark, CM | 1 |
Almqvist, EW | 1 |
Raymond, LA | 1 |
Graf, P | 1 |
Jacova, C | 1 |
Mezei, M | 1 |
Hardy, MA | 1 |
Snow, B | 1 |
Martin, W | 1 |
Hayden, MR | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 1.39 |
B - Placebo | 1.43 |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 4.29 |
B - Placebo | 5.06 |
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.93 |
B - Placebo | -8.02 |
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -26.30 |
B - Placebo | -24.86 |
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -14.21 |
B - Placebo | -14.51 |
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.57 |
B - Placebo | -8.61 |
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -15.25 |
B - Placebo | -19.13 |
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -10.95 |
B - Placebo | -11.36 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -4.53 |
B - Placebo | -4.76 |
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 18.06 |
B - Placebo | 19.18 |
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -5.07 |
B - Placebo | -4.47 |
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | rank (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 303.3 |
B - Placebo | 306.7 |
(NCT00608881)
Timeframe: 5 years
Intervention | participants completing study on drug (Number) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 98 |
B - Placebo | 108 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 917 |
B - Placebo | 911 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 553 |
B - Placebo | 549 |
1 review available for lamotrigine and Huntington Disease
Article | Year |
---|---|
[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities].
Topics: Aged; Aging; Alzheimer Disease; Calcium Channel Blockers; Cerebellar Diseases; Dementia; Electron Tr | 1997 |
2 trials available for lamotrigine and Huntington Disease
Article | Year |
---|---|
Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography.
Topics: Anticonvulsants; Case-Control Studies; Caudate Nucleus; Deoxyglucose; Double-Blind Method; Female; F | 1995 |
Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.
Topics: Adult; Anticonvulsants; Brain; Double-Blind Method; Female; Humans; Huntington Disease; Lamotrigine; | 1999 |
3 other studies available for lamotrigine and Huntington Disease
Article | Year |
---|---|
Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity.
Topics: Amines; Animals; Body Weight; Brain; Catalase; Cyclohexanecarboxylic Acids; GABAergic Neurons; Gabap | 2012 |
Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.
Topics: Amines; Animals; Apoptosis; Cells, Cultured; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Anta | 2006 |
Lamotrigine in motor and mood symptoms of Huntington's disease.
Topics: Antimanic Agents; Atrophy; Caudate Nucleus; Cerebral Cortex; Chorea; Female; Humans; Huntington Dise | 2008 |